Johnson & Johnson (JNJ): Healthcare Stock With Fisher and Yacktman Among Its Investors


As the latest round of 13F filings showed, Johnson & Johnson (NYSE:JNJ) was in 78 hedge funds’ portfolio at the end of September, which represents a slight increase from 74 hedge funds with JNJ positions at the end of the previous quarter. This is what data provided by Insider Monkey, a website that tracks hedge funds, showed. Among the shareholders of Johnson & Johnson are Donald Yacktman, Ken Fisher, Cliff Asness and others.

Insider Monkey strategy follows the activity of some of the best-performing hedge funds, comprising a database of around 700 hedge funds that amass the lion share of the industry’s capital, which consists of around 8,000 functional hedge funds. If you’d ask most traders, hedge funds are viewed as unimportant, outdated financial vehicles of yesteryear, but experts Insider Monkey hone in on the masters of this club and by observing their stock picks, Insider Monkey has spotted several investment strategies that have historically defeated Mr. Market, such as the small-cap hedge fund strategy surpassed the S&P 500 index by 18 percentage points per year for over the long-term.

Keeping this in mind, let’s see how have hedgies been acting around Johnson & Johnson (NYSE:JNJ)?

At Q3’s end, a total of 78 of the hedge funds tracked by Insider Monkey were long in this stock, up by 5%  over the quarter. With hedgies’ sentiment going up, there exists an “upper tier” of noteworthy hedge fund managers who were significantly upping their positions, such as Yacktman Asset Management, led by Donald Yacktman, which holds the biggest position in Johnson & Johnson (NYSE:JNJ) as of the end of September. Yacktman ha a  $1.84 billion position in Johnson & Johnson, comprising 3.8% of its 13F portfolio. Coming in second is Ken Fisher’s Fisher Asset Management, with a $1.11 billion position, equal to 2.4% of its 13F portfolio. We should also mention Cliff Asness’s AQR Capital Management, Phill Gross and Robert Atchinson’s Adage Capital Management and Jim Simons’s Renaissance Technologies, among other shareholders of the company.

Moreover, there are several investors with new stakes in Johnson & Johnson (NYSE:JNJ). Two Sigma Advisors, managed by John Overdeck and David Siegel, owns the larges stake in Johnson & Johnson (NYSE:JNJ) among new investors, revealing a $26.9 million position in its latest 13F filing. In addition, Matthew Tewksbury’s Stevens Capital Management also initiated a $23.3 million position during the third quarter. The following funds were also among the new JNJ investors: Benjamin A. Smith’s Laurion Capital Management, Peter Muller’s PDT Partners, and David Costen Haley’s HBK Investments.

Suggested Articles:

Best TED Talks of All Time

Countries With Best Quality of Life

$GOOG and $TWTR Among Favorite Tech Picks of Bloom Tree Partners$GOOG, $FLT, $CMCSA, $LNG, $TWTR